To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Newly approved CAR-T cell treatments inspire hope in patients with blood cancer.
Silas Inman
Ivosidenib (AG-120) was granted a priority review designation by the Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.
Kristie L. Kahl
Kymriah, which is the first FDA-approved CAR-T cell therapy, is showing promising results in pediatric patients with acute lymphoblastic leukemia.
Brielle Urciuoli
While causes for pneumonia were varied – including bacteria (14 percent), virus (22 percent) and unspecified (64 percent) – the majority of children did not have immune deficiencies recorded at the time of their pneumonia diagnosis.
Brielle Urciuoli
Health care practitioners were surprised when they saw 10 cases of a very rare cancer in the New York City area. As it turned out, most of the patients weren't originally from New York.
William G. Wierda, M.D., Ph.D.
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
Nicole Lamanna, MD, reminds patients with chronic lymphocytic leukemia about current research efforts and new therapies that are helping to transform how CLL is managed. Additionally, Dr. Lamanna offers advice to newly diagnosed patients.
Nicole Lamanna, MD, highlights unmet needs in chronic lymphocytic leukemia and suggests techniques health care professionals and patients can use to improve care.
Nicole Lamanna, MD, explains what refractory disease in chronic lymphocytic leukemia means and remarks on the importance of clinical trials and the use of stem cell transplantation for appropriate patients in this setting.
Nicole Lamanna, MD, defines relapse in chronic lymphocytic leukemia and remarks on considerations for selecting treatment in this setting.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable